[go: up one dir, main page]

CO5170412A1 - Tratamiento del carcinoma de celula renal - Google Patents

Tratamiento del carcinoma de celula renal

Info

Publication number
CO5170412A1
CO5170412A1 CO00025239A CO00025239A CO5170412A1 CO 5170412 A1 CO5170412 A1 CO 5170412A1 CO 00025239 A CO00025239 A CO 00025239A CO 00025239 A CO00025239 A CO 00025239A CO 5170412 A1 CO5170412 A1 CO 5170412A1
Authority
CO
Colombia
Prior art keywords
interferon
cell carcinoma
renal cell
peg
modified
Prior art date
Application number
CO00025239A
Other languages
English (en)
Inventor
Esther Helen Rose
Rybak Mary Ellen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5170412A1 publication Critical patent/CO5170412A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar un paciente que tiene carcinoma de célula renal (RCC - por su siglas en inglés) que comprende administrar a dicho paciente una dosis terapéuticamente efectiva de interferón alfa modificado con polietilén glicol (PEG), tal como interferón alfa-2 modificado con PEG o interferón alfa-2b modificado con PEG, durante un periodo de tiempo suficiente como para lograr al menos una respuesta tumoral parcial.
CO00025239A 1999-04-08 2000-04-06 Tratamiento del carcinoma de celula renal CO5170412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
CO5170412A1 true CO5170412A1 (es) 2002-06-27

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00025239A CO5170412A1 (es) 1999-04-08 2000-04-06 Tratamiento del carcinoma de celula renal

Country Status (24)

Country Link
EP (2) EP1043025B1 (es)
JP (2) JP4721488B2 (es)
CN (1) CN1367702A (es)
AR (1) AR029160A1 (es)
AT (2) ATE419002T1 (es)
AU (2) AU777406B2 (es)
BR (1) BR0009644A (es)
CA (1) CA2303752A1 (es)
CO (1) CO5170412A1 (es)
CY (1) CY1108919T1 (es)
DE (2) DE60041291D1 (es)
DK (2) DK1043025T3 (es)
ES (2) ES2319777T3 (es)
HK (2) HK1032533A1 (es)
HU (1) HU230271B1 (es)
MX (1) MXPA00003401A (es)
MY (1) MY155221A (es)
NO (1) NO328983B1 (es)
NZ (1) NZ514629A (es)
PE (1) PE20010026A1 (es)
PT (2) PT1535623E (es)
TW (2) TWI310314B (es)
WO (1) WO2000061174A2 (es)
ZA (1) ZA200108169B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310314B (en) * 1999-04-08 2009-06-01 Schering Corp Pharmaceutical compositions for treating rental cell carcinoma
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
EP2552443B1 (en) 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
TWI310314B (en) * 1999-04-08 2009-06-01 Schering Corp Pharmaceutical compositions for treating rental cell carcinoma

Also Published As

Publication number Publication date
HUP0200781A2 (en) 2002-08-28
AU2004242454A1 (en) 2005-01-20
CA2303752A1 (en) 2000-10-08
HK1032533A1 (en) 2001-07-27
CN1367702A (zh) 2002-09-04
EP1535623A1 (en) 2005-06-01
TW200526243A (en) 2005-08-16
WO2000061174A2 (en) 2000-10-19
DE60041291D1 (de) 2009-02-12
JP4721488B2 (ja) 2011-07-13
NO20014851L (no) 2001-12-07
BR0009644A (pt) 2002-01-08
JP2000319196A (ja) 2000-11-21
JP3712914B2 (ja) 2005-11-02
HK1075417A1 (en) 2005-12-16
AR029160A1 (es) 2003-06-18
ATE419002T1 (de) 2009-01-15
HU230271B1 (hu) 2015-11-30
EP1043025A3 (en) 2000-12-20
DK1535623T3 (da) 2009-04-27
AU777406B2 (en) 2004-10-14
TWI310314B (en) 2009-06-01
ES2319777T3 (es) 2009-05-12
ES2239953T3 (es) 2005-10-16
PE20010026A1 (es) 2001-02-05
EP1535623B1 (en) 2008-12-31
ZA200108169B (en) 2003-01-06
DE60020442D1 (de) 2005-07-07
AU2004242454B2 (en) 2007-02-15
ATE296638T1 (de) 2005-06-15
NZ514629A (en) 2004-02-27
JP2001288110A (ja) 2001-10-16
EP1043025B1 (en) 2005-06-01
MXPA00003401A (es) 2002-03-08
PT1535623E (pt) 2009-03-19
AU4204400A (en) 2000-11-14
WO2000061174A3 (en) 2001-01-25
CY1108919T1 (el) 2014-07-02
NO20014851D0 (no) 2001-10-05
PT1043025E (pt) 2005-09-30
EP1043025A2 (en) 2000-10-11
DE60020442T2 (de) 2006-05-04
NO328983B1 (no) 2010-07-05
HUP0200781A3 (en) 2002-09-30
MY155221A (en) 2015-09-30
DK1043025T3 (da) 2005-07-04

Similar Documents

Publication Publication Date Title
CO5241354A1 (es) Terapia de combinacio para vhc
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
EA200401525A1 (ru) Способы лечения гепатита (варианты )
NO20032027D0 (no) Effektive antitumorbehandlinger
CO5170412A1 (es) Tratamiento del carcinoma de celula renal
DK1030667T3 (da) Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
AR069767A1 (es) Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa)
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
EA201101036A1 (ru) Применение хлорида аммония в терапии
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
ECSP003418A (es) Tratamiento del carcinoma de celula renal
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
AR077460A1 (es) Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple
CO5170404A1 (es) Terapia para melanomas
ECSP003446A (es) Terapia de combinacion para vhc
ECSP003413A (es) Terapia para la leucemia mielocitica cronica
UA109672C2 (uk) Застосування кислої лізосомної ліпази для лікування дефіциту кислої лізосомної ліпази у хворих

Legal Events

Date Code Title Description
FC Application refused